🇨🇦 GSK1838262 600 mg in Canada

GSK1838262 600 mg (GSK1838262 600 mg) regulatory status in Canada.

Marketing authorisation

GSK1838262 600 mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GSK1838262 600 mg approved in Canada?

Yes. Health Canada has authorised it.

Who is the marketing authorisation holder for GSK1838262 600 mg in Canada?

XenoPort, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.